Rivaroxaban in Paediatric Patients Beyond Clinical Trial Settings – A Real-World Retrospective Cohort Study
Hämostaseologie · 2026-07-29
DOI: 10.1055/a-2918-8110 ↗Abstract
Abstract Background Direct oral anticoagulants (DOACs) show increasing popularity in the treatment of paediatric venous thromboembolism (VTE), but real-world evidence outside clinical trials remains scarce. Objectives This study aimed to evaluate the use, safety and effectiveness of rivaroxaban in a real-world paediatric cohort at a tertiary care hospital. Methods All children exposed to rivaroxaban between January 2020 and June 2025 at our institution were included into this single-centre retrospective cohort study. In chart reviews, effectiveness was assessed as thrombus recurrence, progression, resolution, or improvement; safety outcomes included clinically relevant bleeding (CRB) and minor bleeding. Results Fifty-seven children were included at a median age of 13.8 years (IQR 7.1–15.6); 49% were female. In the treatment group (n = 37), one thrombosis recurred (3%), with thrombus resolution in 19 (54%) and radiologic improvement in 5 patients (14%). In the prophylaxis group (n = 20), no incident VTE occurred. Overall, CRB was rare (7%), all non-major during rivaroxaban exposure and occurred exclusively in children with identifiable additional bleeding risk factors. Conclusions Rivaroxaban demonstrated a favourable effectiveness and safety profile in this real-world paediatric cohort, with outcomes comparable to available real-world and trial data. CRB events clustered in settings with additional bleeding risks, underscoring the importance of patient characteristics in guiding therapy. Our findings support rivaroxaban as a feasible anticoagulation option in children.
EUVIMED